CREATE LINK
Recently, Wu Chuangzhi, Secretary of the Party Committee of the Shenzhen Advanced Technology Research Institute of the Chinese Academy of Sciences (hereinafter referred to as "Shenzhen Advanced Institute"), Qiu Liyang, Head of the Innovation R&D Center of the China Europe Innovative Medicine and Health Research Center (hereinafter referred to as "China Europe Medical Center"), and Jia Jianyu, Deputy Director of the Hohhot Science and Technology Bureau, visited Inner Mongolia Jinyuankang Biotechnology Co., Ltd. (hereinafter referred to as "Jinyuankang Biotechnology") on site. This deep link focuses on technology collaboration, industry implementation, and achievement transformation, aiming to build a cooperation bridge between research institutes, industry platforms, and local enterprises, help promote the deep integration of the biopharmaceutical innovation chain and industry chain, and promote the high-quality development of the regional biopharmaceutical industry.
Jinyuankang Biotechnology focuses on the field of biomedicine, deeply cultivating the research and development of cell culture media, raw materials, and large-scale production. It has mature production processes, perfect quality systems, and efficient industrial supporting capabilities, and is a benchmark enterprise with core technological advantages and industrialization strength in the region. The docking and cooperation between Shenzhen Advanced Institute, China Europe Medical Center, and Jinyuankang Biotechnology is an important milestone in the collaborative innovation of industry, academia, and research, laying a solid foundation for connecting the entire chain of scientific research and innovation, pilot scale transformation, and industrial landing.
During the visit, Wu Chuangzhi, Secretary of the Party Committee of Shenzhen Advanced Institute, and other leaders visited the exhibition hall, production workshop, technology platform, and culture medium workshop of Jinyuankang Biotechnology to comprehensively understand the company's R&D system, production scale, and quality control capabilities. Subsequently, the core management team including Zhao Junfeng, Chairman of Jinyuankang Biotechnology, and Su Ye, General Manager, held discussions with the team on key issues such as technological breakthroughs, service co construction, and pipeline transformation, and reached multiple pragmatic cooperation consensuses.
Wu Chuangzhi, Secretary of the Party Committee of Shenzhen Advanced Institute, highly recognizes the industrialization strength of Jinyuankang Biotechnology in the field of cell culture media and raw materials, and expresses that Shenzhen Advanced Institute has always focused on breakthroughs in cutting-edge research in biomedicine. He hopes to take this as an opportunity to fully leverage the research advantages of the institute, work together with the China Europe Medical Center to connect the entire chain of "scientific research innovation pilot transformation industrial landing", achieve key technological breakthroughs in special cell culture media, CGT pipeline development and other fields, and empower the upgrading of the regional biopharmaceutical industry with technology.
The Chairman of Jinyuankang Biotechnology mentioned that Jinyuankang Biotechnology has been deeply involved in the research and production of cell culture media and biopharmaceutical raw materials for many years, and has always adhered to technological independence and deep industry cultivation. We are very much looking forward to working closely with Shenzhen Advanced Institute and China Europe Pharmaceutical Center, relying on the advantages of the three parties' resources, to implement joint innovation and industrial service projects. The enterprise will fully exert its production supporting and process implementation capabilities, promote the rapid transformation of cooperation results, and help Inner Mongolia's biopharmaceutical industry develop with high quality.
This visit further deepened the cooperation foundation between Shenzhen Advanced Institute, China Europe Medical Center, and Jinyuankang Biotechnology, achieving efficient complementarity of scientific research advantages, industrial capabilities, and regional resources. In the future, the three parties will use collaborative innovation as the engine to continuously deepen technology research and development, industrial services, and project transformation, jointly promote the upgrading of the biopharmaceutical industry, and inject strong momentum into the construction of a healthy China and regional economic development.
The article is sourced from the China Europe Innovation Center for Medicine and Health Research
Scan to follow